TGTX Tg Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TGTX

Price (delayed)

$53.31

Market cap

$8.16B

P/E Ratio

16.56

Dividend/share

N/A

EPS

$3.22

Enterprise value

$8.47B

?
Relative Growth: Rel. Growth: 96
Relative Strength: Rel. Strength: 88
Relative Valuation: Rel. Valuation: 69
Relative Profitability: Rel. Profitability: 98

TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active ...

Highlights
The revenue has soared by 81% YoY and by 14% QoQ
Tg Therapeutics's gross profit has surged by 72% YoY and by 13% QoQ
The equity has surged by 146% year-on-year but it has declined by 10% since the previous quarter
TGTX's debt has soared by 198% YoY and by 198% QoQ
The gross margin has decreased by 4.9% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.tgtherapeutics.com
Peers: ALKS NERV

Key stats

What are the main financial stats of TGTX

TGTX stock price

How has the Tg Therapeutics stock price performed over time
Intraday
-0.39%
1 week
-0.6%
1 month
45.5%
1 year
46.9%
YTD
78.83%
QTD
-2.97%

Financial performance

How have Tg Therapeutics's revenue and profit performed over time
Revenue
$700.35M
Gross profit
$581.67M
Operating income
$149.5M
Net income
$461.9M
Gross margin
83.1%
Net margin
66%
The operating income has soared by 150% YoY and by 21% from the previous quarter
The revenue has soared by 81% YoY and by 14% QoQ
Tg Therapeutics's gross profit has surged by 72% YoY and by 13% QoQ
Tg Therapeutics's operating margin has increased by 37% YoY and by 7% QoQ

Price vs fundamentals

How does TGTX's price correlate with its fundamentals

Growth

What is Tg Therapeutics's growth rate over time

Valuation

What is Tg Therapeutics stock price valuation
TGTX P/E details
P/E
16.56
P/B
14.6
P/S
10.99
EV/EBIT
56.49
EV/EBITDA
56.46
EV/Sales
12.09
The P/E is 45% lower than the last 4 quarters average of 29.9
Tg Therapeutics's EPS has increased by 3.9% QoQ
The equity has surged by 146% year-on-year but it has declined by 10% since the previous quarter
The P/B is 33% below the 5-year quarterly average of 21.9 but 26% above the last 4 quarters average of 11.6
The P/S is 93% below the 5-year quarterly average of 150.2 but 25% above the last 4 quarters average of 8.8
The revenue has soared by 81% YoY and by 14% QoQ

Efficiency

How efficient is Tg Therapeutics business performance
Tg Therapeutics's return on sales has increased by 18% YoY
The ROA has contracted by 18% from the previous quarter
TGTX's ROIC is down by 15% QoQ and by 3.6% YoY
The company's return on equity fell by 14% QoQ

Dividends

What is TGTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TGTX.

Financial health

How did Tg Therapeutics financials performed over time
The total assets is 62% higher than the total liabilities
The total assets has soared by 133% YoY and by 44% QoQ
Tg Therapeutics's total liabilities has surged by 128% QoQ and by 125% YoY
TGTX's debt is 29% higher than its equity
TGTX's debt has soared by 198% YoY and by 198% QoQ
The equity has surged by 146% year-on-year but it has declined by 10% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.